Healthcare systems have had to adapt to evolving challenges in recent years, and in response, the pharmaceutical and biotechnology sectors have implemented different innovative pricing and reimbursement models. In an article for MedTech Strategist, we explore whether similar innovative reimbursement and contracting schemes might be developed for medical technologies and how the challenges they bring might be overcome.
Measuring and mitigating harm from discriminatory taxes
In the article the authors examine the April 2 Executive Order signed by President Trump highlighting US trading partners’ nontariff barriers, such as...